Samir P. Tabash

Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicity

John Choe, Stephen A. Strugnell, Samir P. Tabash, Akhtar Ashfaq

Intrinsic diurnal variation of serum calcifediol (25-hydroxyvitamin D 3 ) was evaluated in healthy United States (US) adults by race, gender and age. Eligible participants (18-55 years old, body mass index 18-30 kg/m 2 , body weight ≥50 kg) were enrolled with …

us, gb (code pays fourni par la source)

High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report

Akhtar Ashfaq, John Choe, Samir P. Tabash, Stephen A. Strugnell et autres

BACKGROUND: Hemodialysis (HD) patients lose renal CYP27B1 (cytochrome P450 25-hydroxyvitamin D-1α-hydroxylase) as kidney function declines causing low serum total 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), and elevated intact parathyroid hormone (iPTH). Most require vitamin D hormone treatment which increases the risk …

us, gb (code pays fourni par la source)

High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report

Akhtar Ashfaq, John Choe, Samir P. Tabash, Stephen A. Strugnell et autres

ie, nl (code pays fourni par la source)

LBSAT230 Daily Variation In Serum Calcifediol In Japanese And Non-japanese Adults

Akhtar Ashfaq, Stephen A. Strugnell, Samir P. Tabash, Charles W. Bishop

Abstract Circadian rhythm and 24-hour intra-subject variation in serum calcifediol (25-hydroxyvitamin D3) in the absence of vitamin D supplementation or treatment are poorly studied in healthy adults of any race. To address this dearth of information, a single-center, open-label study was completed …

us (code pays fourni par la source)

LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.

Akhtar Ashfaq, Stephen A. Strugnell, Samir P. Tabash, Laura A. Johnson et autres

Abstract Background Extended-release calcifediol (ERC) has been shown in randomized clinical trials to effectively and safely treat secondary hyperparathyroidism (SHPT) in adults with stage 3-4 chronic kidney disease (CKD) and vitamin D insufficiency when administered at 210 or 420 mcg per week …

us (code pays fourni par la source)

Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation

Martin P. Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash et autres

Vitamin D insufficiency is prevalent in chronic kidney disease (CKD) and associated with secondary hyperparathyroidism (SHPT) and increased risk of bone and vascular disease. Unfortunately, supplementation of stage 3 or 4 CKD patients with currently recommended vitamin D2 or D3 regimens does …

ca, us (code pays fourni par la source)

Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

Stuart Michael Sprague, Arnold L. Silva, Fahd Al-Saghir, Radhika Damle et autres

BACKGROUND/AIMS: Vitamin D insufficiency drives secondary hyperparathyroidism (SHPT) and is associated with increased cardiovascular mortality in patients with chronic kidney disease (CKD). SHPT is poorly addressed by current vitamin D repletion options. The present study evaluated a novel investigational vitamin D repletion …

us, ca (code pays fourni par la source)

Position Statement from ADA/AACE/EASD/TES in Response to a Recently Published Letter to the Editor in The Lancet and an Editorial Addressing the Israeli-Palestinian Fighting in Gaza

Wei Deng, Yile Ren, Xuebing Feng, Genhong Yao et autres

Contents Vol. 40, 2014

Wei Deng, Yile Ren, Xuebing Feng, Genhong Yao et autres

Acknowledgement to the Reviewers

Wei Deng, Yile Ren, Xuebing Feng, Genhong Yao et autres

Dysregulation of renal vitamin D metabolism in the uremic rat

Christian F. Helvig, Dominic Cuerrier, Christopher M. Hosfield, Breanna Ireland et autres

ca (code pays fourni par la source)

CYP1A Induction and Blue SAC Disease in Early Developmental Stages of Rainbow Trout (Oncorhynchus Mykiss) Exposed to Retene

Lyndon Brinkworth, Peter V. Hodson, Samir P. Tabash, Patricia J. Lee

Early life stages of rainbow trout were exposed to different regimes of water-borne retene (7-isopropyl-1-methylphenanthrene) to determine if there is an ontogenic stage particularly sensitive to retene toxicity, and if cytochrome P-4501A (CYP1A) induction is a forerunner to blue sac disease (BSD), …

ca (code pays fourni par la source)